Liquidia Corp rises on plans to seek full approval for blood disorder drug

Liquidia

01/04/2024 13:24

** Shares of drug developer Liquidia Corp  LQDA.O  rise 7.5%
to $15.85 premarket
    ** Co said it can now seek full approval for its blood
pressure drug after U.S. district court of Delaware set aside
the patent infringement lawsuit that was filed by United
Therapeutics  UTHR.O  in August 2022 
     ** "We have submitted the judge's order to the FDA and look
forward to a decision from the FDA in the near future"- CEO
Roger Jeffs
    ** FDA in January said it is still reviewing co's marketing
application for possible approval of the drug to expand its use
to treat a progressive blood vessel disorder related to a lung
condition
    ** The drug was granted tentative approval in 2021 to treat
pulmonary arterial hypertension
    ** However, LQDA could not market the drug in the U.S. due
to a regulatory stay related to a patent infringement dispute
with UTHR 
    ** Up to last close, LQDA has risen 22.6% YTD 

 (Reporting by Sneha S K in Bengaluru)
 ((Sneha.SK@thomsonreuters.com;))